[Autoimmune bullous skin disorders].

Area of Science:

• Dermatology
• Immunology
• Pathology

Context:

• Autoimmune bullous skin disorders are rare but potentially fatal conditions.
• These diseases are characterized by autoantibodies targeting skin adhesion molecules.
• Clinical presentation includes blisters and erosions due to loss of skin adhesion.

Purpose:

• To review the pathogenesis, diagnosis, and therapeutic strategies for autoimmune bullous skin disorders.
• To highlight advancements in understanding autoantigens and diagnostic methods.
• To discuss current and emerging treatment options.

Summary:

• Autoimmune bullous disorders are mediated by IgG or IgA autoantibodies against epidermal or dermal-epidermal adhesion molecules.
• Diagnosis relies on histology, direct immunofluorescence, and serological detection of autoantibodies using indirect immunofluorescence and recombinant autoantigens.
• Treatment involves systemic glucocorticoids with immunosuppressive adjuvants, topical therapies (e.g., clobetasol for bullous pemphigoid), and B-cell depletion (e.g., rituximab for pemphigus).

Impact:

• Improved diagnostic accuracy through advanced immunofluorescence and recombinant autoantigen techniques.
• Reduced systemic steroid dosage and side effects with adjuvant immunosuppressants and topical treatments.
• Enhanced prognosis for pemphigus with the introduction of rituximab therapy, though further trials are needed for other conditions.